Home›Trial›NCT06173531
NCT06173531Phase 3ACTIVE NOT RECRUITING

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Study Summary

12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)

Conditions
Hyperphagia in Prader-Willi Syndrome
Interventions / Drugs
CarbetocinPlacebo
View on ClinicalTrials.gov ↗
Sponsor
ACAD
ACADIA Pharmaceuticals
Neuroscience
B77/100
Study Details
Enrollment170 participants
Primary Completion—
Lead SponsorACADIA Pharmaceuticals Inc.
Data Retrieved2026-04-11 02:52:05.277053+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 170 participants
Sponsor Catalyst Profile

ACADIA Pharmaceuticals (ACAD) is the sponsoring company for this trial. BiotechSign currently grades this company B (77/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ACAD Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.